01:02 PM EDT, 04/01/2024 (MT Newswires) -- OptimizeRx ( OPRX ) is likely to meet the 2024 guidance it issued last month, according to analysts at RBC Capital Markets.

On March 11, the health technology company said it expects 2024 revenue of at least $100 million, and adjusted earnings before interest, taxes, depreciation, and amortization of more than $11 million.

"Combined with the recent acquisition of Medicx and the benefits from already-executed cost actions, we remain confident in the achievability of '24 guidance," RBC analysts Sean Dodge and Thomas Kelliher said in a note to clients.

RBC also highlighted that the company is expecting strong sales growth seen in Q4 to continue into Q1 as the macro environment is improving.

The investment firm has outperform rating on OptimizeRx's ( OPRX ) stock with a price target of $17.

Shares of OptimizeRx ( OPRX ) were down 4.5% in recent trading.

Price: 11.61, Change: -0.54, Percent Change: -4.44